CLLS Cellectis S.A.

Nasdaq cellectis.com


$ 4.13 $ -0.06 (-1.44 %)    

Wednesday, 15-Oct-2025 15:59:52 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 4.11
$ 4.10
$ 4.00 x 297
$ 4.54 x 201
$ 4.00 - $ 4.20
$ 1.10 - $ 4.59
74,174
na
411.39M
$ 2.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

 inventiva-moonlake-immunotherapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiv...

 why-merus-shares-are-trading-higher-by-38-here-are-20-stocks-moving-premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus fo...

 top-5-biotech-stocks-with-strong-momentum

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

 barclays-maintains-overweight-on-cellectis-lowers-price-target-to-4

Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and lowers the price target from $5 to $4.

 cellectis-q1-adj-eps-017-beats-023-estimate-sales-1203m-miss-1461m-estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by ...

 cellectis-presents-research-data-on-talen-and-taleb-technologies-for-gene-and-cellular-therapies-at-asgct-annual-meeting

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

 cellectis-q4-2024-adj-eps-016-beats-017-estimate-sales-3322m-beat-945m-estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by ...

 cellectis-showcases-new-car-t-cell-strategy-to-fight-solid-tumors-at-aacr-io

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION